Myelofibrosis Pipeline Insights, Clinical Trials Assessment, Emerging Drugs, FDA Approvals and Companies | DelveInsight

DelveInsight's, "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Myelofibrosis Research. Learn more about our innovative pipeline today! @ Myelofibrosis Pipeline Outlook- https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Myelofibrosis Pipeline Report
• In January 2025:- AbbVie:- A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
• In January 2025:- Celgene:- The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions.
• In January 2025:- Stemline Therapeutics Inc.:- This multicenter, multi-arm trial evaluated the safety and efficacy of tagraxofusp, a cell division cycle protein 123 homolog-targeted therapy, in participants with either CMML or MF. There were 2 CMML cohorts, 1 enrolled participant with CMML (CMML-1 or CMML-2) who were refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), or intensive chemotherapy and 1 enrolled treatment-naive participants with CMML (CMML-1 or CMML-2) with molecular features associated with poor prognosis.
• DelveInsight's Myelofibrosis pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Myelofibrosis treatment.
• The leading Myelofibrosis Companies such as Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.
• Promising Myelofibrosis Therapies such as Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.

Stay informed about the cutting-edge advancements in Myelofibrosis treatments. Download for updates and be a part of the revolution in care @ Myelofibrosis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Myelofibrosis Emerging Drugs Profile
• Imetelstat: Geron Corporation
Imetelstat sodium (imetelstat) is a small oligonucleotide composed of a nucleic acid and a lipid moiety. The proprietary nucleic acid backbone provides resistance to degradation, thus conferring improved stability in plasma and tissues, as well as significantly improved binding affinity to its target. The lipid group enhances cell permeability, which results in increased potency and improved pharmacokinetic and pharmacodynamic properties. The compound has a long residence time in bone marrow, spleen, and liver. Imetelstat binds with high affinity to the template region of the RNA component of telomerase, resulting in direct, competitive inhibition of telomerase enzymatic activity rather than eliciting its effect through an antisense inhibition of protein translation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Myelofibrosis.

• Bomedemstat: Merck
Bomedemstat is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme critical for regulating the proliferation of hematopoietic stem cells and the maturation of progenitors. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Myelofibrosis.

• TL-895: Telios Pharma, Inc.
It is an orally bioavailable inhibitor of tyrosine kinase, with potential anti-inflammatory and antineoplastic activities. Upon oral administration, tyrosine kinase inhibitor TL-895 targets, binds to, and inhibits tyrosine kinase. This may result in the inhibition of tumor angiogenesis and cell proliferation, and the inhibition of immune-mediated inflammatory processes. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Myelofibrosis.

• RVU120: Ryvu Therapeutics SA
RVU120 is a selective, first-in-class dual CDK8/19 kinase inhibitor developed by Ryvu Therapeutics. RVU120's mechanism of action (MoA) involves targeting CDK8/19 kinases. Specifically, translational data confirm the proposed MoA in a molecularly-defined subset of patients with DNMT3A and NPM1 mutations. Currently, the drug is in the Phase II stage of development to treat Myelofibrosis.

• TBX-2400: Taiga Biotechnologies, Inc.
TBX-2400 is an allogeneic stem cell therapy developed by Taiga Biotechnologies that aims to improve the rate of engraftment and reconstitution of the immune system for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Currently, the drug is in the Phase I stage of development to treat Myelofibrosis.

Learn more about Myelofibrosis Drugs opportunities in our groundbreaking Myelofibrosis Research and development projects @ Myelofibrosis Unmet Needs- https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Myelofibrosis Companies
Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Myelofibrosis Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Myelofibrosis treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Myelofibrosis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Myelofibrosis Pipeline Report
• Coverage- Global
• Myelofibrosis Companies- Geron Corporation, Merck, Telios Pharma Inc., Ryvu Therapeutics SA, Taiga Biotechnologies, Inc., Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., and others.
• Myelofibrosis Therapies- Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.
• Myelofibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myelofibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Myelofibrosis Pipeline on our website @ Myelofibrosis Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Myelofibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myelofibrosis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Imetelstat: Geron Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RVU120: Ryvu Therapeutics SA
12. Drug profiles in the detailed report…..
13. TBX-2400: Taiga Biotechnologies, Inc.
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Myelofibrosis Key Companies
20. Myelofibrosis Key Products
21. Myelofibrosis- Unmet Needs
22. Myelofibrosis- Market Drivers and Barriers
23. Myelofibrosis- Future Perspectives and Conclusion
24. Myelofibrosis Analyst Views
25. Appendix

List of Top Selling Market Research Reports in 2025
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
NK cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
testicular neoplasm market- https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
skin neoplasm market- https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
cardiac implantable electronic devices market- https://www.delveinsight.com/blog/implantable-cardiac-monitors-market
dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
catheter stabilization devices market- https://www.delveinsight.com/sample-request/catheter-stabilization-securement-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.